Glaukos Corp (NYSE:GKOS) – Equities research analysts at Piper Jaffray Companies cut their Q3 2020 earnings per share estimates for shares of Glaukos in a report released on Wednesday, November 7th. Piper Jaffray Companies analyst M. O’brien now anticipates that the medical instruments supplier will earn $0.00 per share for the quarter, down from their prior forecast of $0.05. Piper Jaffray Companies has a “Overweight” rating and a $73.00 price target on the stock.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, November 7th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $43.91 million during the quarter, compared to the consensus estimate of $41.65 million. Glaukos had a negative net margin of 8.13% and a negative return on equity of 9.58%. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.04 earnings per share.

GKOS has been the topic of a number of other reports. Stephens boosted their price target on Glaukos from $57.00 to $70.00 and gave the company an “overweight” rating in a report on Monday, September 10th. BMO Capital Markets lifted their target price on Glaukos from $59.00 to $68.00 and gave the company a “market perform” rating in a research report on Wednesday, September 5th. Wells Fargo & Co lifted their target price on Glaukos from $50.00 to $74.00 and gave the company an “outperform” rating in a research report on Thursday, August 30th. JPMorgan Chase & Co. raised Glaukos from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $42.00 to $75.00 in a research report on Wednesday, August 29th. Finally, Zacks Investment Research downgraded Glaukos from a “hold” rating to a “sell” rating in a research report on Friday, November 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $58.20.

Shares of Glaukos stock opened at $61.28 on Friday. Glaukos has a one year low of $23.08 and a one year high of $70.91.

In related news, Director Gilbert H. Kliman sold 502,760 shares of Glaukos stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $60.39, for a total value of $30,361,676.40. The transaction was disclosed in a filing with the SEC, which is available at this link. 11.60% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in GKOS. NumerixS Investment Technologies Inc acquired a new stake in shares of Glaukos in the second quarter valued at about $127,000. Great West Life Assurance Co. Can increased its position in Glaukos by 112.0% during the second quarter. Great West Life Assurance Co. Can now owns 4,240 shares of the medical instruments supplier’s stock worth $172,000 after buying an additional 2,240 shares during the last quarter. Valeo Financial Advisors LLC acquired a new position in Glaukos during the second quarter worth approximately $183,000. Prudential Financial Inc. acquired a new position in Glaukos during the third quarter worth approximately $203,000. Finally, Amalgamated Bank acquired a new position in Glaukos during the second quarter worth approximately $205,000.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Recommended Story: The Discount Rate – What You Need to Know

Earnings History and Estimates for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.